EducationNCT06138379
Video-supported Training in Line With the Health Belief Model
A study testing Experimental: 1st Experimental Group and Experimental: 2nd Experimental Group in people with Education, run by Inonu University at 1 site in Turkey (Türkiye).
Trial summary
Summary The only treatment method for those with incurable, irreversible, progressive, acute or chronic liver disease is liver transplantation. Compliance with the disease and immunosuppressive treatment has an important place in the success of transplants. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Education
- What is being tested?
- Experimental: 1st Experimental Group and Experimental: 2nd Experimental Group
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Dec 2023to 16 Aug 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Those who are 18 years of age and over,
- At least 2 months and at most 2 years have passed since the transplant,
- Having a device (phone, tablet, computer, etc.) that can watch the video,
- Patients who are literate will be included in the study.
Who cannot join
- Communication problems occur,
- Patients with distressing medical conditions will be excluded from the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Video-Assisted Education Given to Patients With Liver Transplantation in the Line of Health Belief Model on Adaptation to Disease and Drug Use
Summary The only treatment method for those with incurable, irreversible, progressive, acute or chronic liver disease is liver transplantation. Compliance with the disease and immunosuppressive treatment has an important place in the success of transplants. This study was planned to examine the effect of video-supported education given to liver transplant patients in line with the Health Belief Model on adaptation to chronic disease and medication use.
The research will be conducted as a randomized controlled experimental study. The population of the research will consist of adult patients who received liver transplantation at İnönü University Turgut Özal Medical Center. The sample will consist of 90 patients determined by power analysis. Patients will be divided into three groups: control (n=30), 1st experiment (n=30) and 2nd experiment (n=30). Data will be collected between August 2023 and December 2023 using the Patient Information Form, Chronic Disease Adaptation Scale, Immunosuppressive Drug Use Compliance Scale and Rational Drug Use Scale. Video-supported training will be provided to patients in the experimental group to increase compliance with the disease and immunosuppressive treatment and to ensure rational drug use. Patients in the 1st experimental group will receive video-supported training in line with the Health Belief Model for one month, and patients in the 2nd experimental group will receive video-supported standard training for one month. This video training will be given to the experimental group patients outside the routine nursing care of the clinic. The video-supported training is planned to last 20-30 minutes. Nursing care in the routine practice of the clinic will be applied to the control group. Evaluation of data; It will be done with number, percentage, mean, standard deviation, chi-square, paired t test, t test analysis in independent groups, ANOVA and ANCOVA.
As a result, it is predicted that video-supported education will increase compliance with chronic disease and medication use and reduce post-transplant symptoms and discomfort caused by these symptoms.
Read the detailed description
Although there are studies on video-supported education in the literature, no research has been found examining the effect of video-assisted education in line with SIM on disease adaptation and medication use in liver transplant patients. For this reason, in this research, it is aimed to minimize the risks by obtaining information about the beliefs and tendencies of the patients, adapting to chronic diseases and medication use, with the video-supported training prepared in line with the use of SIM as an effective tool. The research is unique because it is the first study comparing the education provided with SIM and standard education. When the difference between the training given with SIM and standard training is determined, it can be stated with strong evidence that compliance with the disease and medication may be due to the training given with the model.
- Conditions
- Education
- Being tested
- Experimental: 1st Experimental Group, Experimental: 2nd Experimental Group
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Experimental: 1st Experimental GroupOther
Also called Video-supported teaching in line with the Health Belief Model
Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
Experimental: 2nd Experimental GroupOther
Also called Video assisted teaching
Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
| Study group | Role | What they receive |
|---|---|---|
| Control Group | No intervention | No Intervention: Control group The research will begin after obtaining the necessary legal and ethical permissions to collect data. At this stage of the research, participants who agree to participate in the research will be asked to fill out an informed consent form. All forms will be filled in to obtain pre-test data for the research. These individuals who receive and continue to receive standard care will be informed about the research. Pre-test and post-test data from the control group will be obtained simultaneously with the study groups. |
| 1. Experimental Group | Experimental | Experimental: Experimental group given video-supported training in line with the health belief model.
All forms (Patient Information Monitoring Form, Chronic Disease Adaptation Scale, Rational Drug Use Scale and Immunosuppressive Drug Form Scale) will be filled in to obtain pre-test data for the research. Individuals will be trained according to the training materials prepared for the Health Belief Model. They will be monitored one day each week. After 30 days, all forms will be filled out again to examine the sustainability of the training data. Receives: Other: Experimental: 1st Experimental Group |
| 2. Experimental Group | Experimental | Experimental: The experimental group was given video-supported training in line with Classical Education.
All forms (Patient Information Monitoring Form, Chronic Disease Adaptation Scale, Rational Drug Use Scale and Immunosuppressive Drug Form Scale) will be filled in to obtain pre-test data for the research. Individuals will be trained according to the training materials prepared for the Health Belief Model. They will be monitored one day each week. After 30 days, all forms will be filled out again to examine the sustainability of the training data. Receives: Other: Experimental: 2nd Experimental Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient Introduction Form
It is a form prepared by the researcher and examines the sociodemographic and medical characteristics of liver transplant patients. This form includes 11 questions to determine the patients' age, gender, marital status, education level, employment status, income level, how long they have had liver disease, additional diseases, the presence of people assisting in the care, how long ago the transplant was performed, and the donor type.
Measured: 6 months
Chronic Illness Adjustment Scale
It was developed by Derya Atik and Hilal Karatepe in 2016. The scale consists of 25 items. It consists of three subscales: Physical Adaptation (11 items), Social Adaptation (7 items), and Psychological Adaptation (7 items). Subdimensions of the scale; 1. Physical Harmony; Items 1, 9, 10, 13, 14, 15, 16, 18, 22, 23, 24 (minimum 11, maximum 55 points), 2. Social Cohesion; 2nd, 3rd, 5th, 7th, 17th, 19th, 25th items (minimum 7, maximum 35 points), 3. Psychological Adjustment; Items 4, 6, 8, 11, 12, 20, 21 measure (minimum 7, maximum 35 points). Scoring: 1st, 2nd, 3rd, 4th, 7th, 8th, 9th, 10th, 11th, 13th, 14th, 15th, 16th, 18th, 21st, 22nd, The 23rd items are normal (in the form of 1,2,3,4,5), the 5th, 6th, 12th, 17th, 19th, 20th, 24th, 25th items are reverse (5,4,3,2). It is scored as .1). The total score that can be obtained from the scale is 125. Higher scores from the subscales and/or the entire scale mean that patients' adaptation levels to the disease increase.
Measured: 6 months
Compliance with Immunosuppressive Medication Use Scale
In the scale developed by Özdemir, the compliance with medication use of patients who have had solid organ transplants and are taking immunosuppressive drugs is evaluated. In order for the scale to be applied, patients must complete at least two months after transplantation. The scale consists of 11 items in total. Scoring is done with a 5-point and 2-point Likert type rating. The scale includes positive and negative expressions. Positive statements are 4 and 6, and negative statements are 1, 2, 3, 5, 7, 8, 9, 10 and 11. Positive statements are scored from 1 to 5, while negative statements are scored from 5 to 1. For positive items, 1 point is given for a 'yes' answer and 5 points are given for a 'no' answer. The lowest score of the scale is 11 and the highest score is 55. As the score from the scale increases, compliance with medication use increases, and as the score decreases, compliance with medication use decreases. Cronbach's alpha value was calculated as 0.611 by Özdemir.
Measured: 6 months
Rational Drug Use Scale
It consists of 21 items and a single dimension. Items are scored on a 5-point Likert-type scale according to the situations in which they realize the statements (1-Never, 2-Rarely, 3-Occasionally, 4-Often and 5-Always). Only the 17th item in the scale is reverse scored. After the reverse-scored item is translated, the sum of all scale items gives the "total scale score". The total score of AİKÖ varies between 21 and 105. As the total score obtained from ADAS increases, rational drug use increases. When evaluating the total score received from AİKÖ; If the total score is between 21 and 52, it is scored as low, between 53 and 67, as medium, and between 68 and 105, it is scored as high.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2023
- Study start1 Dec 2023
- Primary completion16 Apr 2024
- Study completion16 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EducationStudies of the same condition, open and under way.
- More trials run by Inonu UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The research will be conducted as a randomized controlled experimental study. The population of the research will consist of adult patients who received liver transplantation at İnönü University Turgut Özal Medical Center. The sample will consist of 90 patients determined by power analysis.
- Masking
- None (open label)
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Inonu University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zeliha CENGİZ, Inonu University
- Investigators
- Sezai Yılmaz, Prof Dr, Study director, Turgut Ozal Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06138379
- Sponsor's protocol ID
- 2023/4674
- Status last verified
- Feb 2026
- First submitted
- 7 Nov 2023
- Last updated
- 12 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: It can be used as a source for other research.
Study at a glance
From the registry record, last updated by the sponsor on 12 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Video-Assisted Education Given to Patients With Liver Transplantation in the Line of Health Belief Model on Adaptation to Disease and Drug Use
- ClinicalTrials.gov ID
- NCT06138379
- Acronym / sponsor ID
- 2023/4674
- Conditions
- Education
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Inonu UniversityUniversity, hospital or other
- Study start
- 1 Dec 2023 (actual)
- Primary completion
- 16 Apr 2024 (actual)
- Study completion
- 16 Aug 2024 (actual)
- First posted
- 18 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Summary The only treatment method for those with incurable, irreversible, progressive, acute or chronic liver disease is liver transplantation. Compliance with the disease and immunosuppressive treatment has an important place in the success of transplants. This study was planned to examine the effect of video-supported education given to liver transplant patients in line with the Health Belief Model on adaptation to chronic disease and medication use.
The research will be conducted as a randomized controlled experimental study. The population of the research will consist of adult patients who received liver transplantation at İnönü University Turgut Özal Medical Center. The sample will consist of 90 patients determined by power analysis. Patients will be divided into three groups: control (n=30), 1st experiment (n=30) and 2nd experiment (n=30). Data will be collected between August 2023 and December 2023 using the Patient Information Form, Chronic Disease Adaptation Scale, Immunosuppressive Drug Use Compliance Scale and Rational Drug Use Scale. Video-supported training will be provided to patients in the experimental group to increase compliance with the disease and immunosuppressive treatment and to ensure rational drug use. Patients in the 1st experimental group will receive video-supported training in line with the Health Belief Model for one month, and patients in the 2nd experimental group will receive video-supported standard training for one month. This video training will be given to the experimental group patients outside the routine nursing care of the clinic. The video-supported training is planned to last 20-30 minutes. Nursing care in the routine practice of the clinic will be applied to the control group. Evaluation of data; It will be done with number, percentage, mean, standard deviation, chi-square, paired t test, t test analysis in independent groups, ANOVA and ANCOVA.
As a result, it is predicted that video-supported education will increase compliance with chronic disease and medication use and reduce post-transplant symptoms and discomfort caused by these symptoms.
Detailed description
Although there are studies on video-supported education in the literature, no research has been found examining the effect of video-assisted education in line with SIM on disease adaptation and medication use in liver transplant patients. For this reason, in this research, it is aimed to minimize the risks by obtaining information about the beliefs and tendencies of the patients, adapting to chronic diseases and medication use, with the video-supported training prepared in line with the use of SIM as an effective tool. The research is unique because it is the first study comparing the education provided with SIM and standard education. When the difference between the training given with SIM and standard training is determined, it can be stated with strong evidence that compliance with the disease and medication may be due to the training given with the model.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- The research will be conducted as a randomized controlled experimental study. The population of the research will consist of adult patients who received liver transplantation at İnönü University Turgut Özal Medical Center. The sample will consist of 90 patients determined by power analysis.
| Arm | Type | Receives |
|---|---|---|
| Control Group | No intervention | –No Intervention: Control group The research will begin after obtaining the necessary legal and ethical permissions to collect data. At this stage of the research, participants who agree to participate in the research will be asked to fill out an informed consent form. All forms will be filled in to obtain pre-test data for the research. These individuals who receive and continue to receive standard care will be informed about the research. Pre-test and post-test data from the control group will be obtained simultaneously with the study groups. |
| 1. Experimental Group | Experimental | Other: Experimental: 1st Experimental GroupExperimental: Experimental group given video-supported training in line with the health belief model. All forms (Patient Information Monitoring Form, Chronic Disease Adaptation Scale, Rational Drug Use Scale and Immunosuppressive Drug Form Scale) will be filled in to obtain pre-test data for the research. Individuals will be trained according to the training materials prepared for the Health Belief Model. They will be monitored one day each week. After 30 days, all forms will be filled out again to examine the sustainability of the training data. |
| 2. Experimental Group | Experimental | Other: Experimental: 2nd Experimental GroupExperimental: The experimental group was given video-supported training in line with Classical Education. All forms (Patient Information Monitoring Form, Chronic Disease Adaptation Scale, Rational Drug Use Scale and Immunosuppressive Drug Form Scale) will be filled in to obtain pre-test data for the research. Individuals will be trained according to the training materials prepared for the Health Belief Model. They will be monitored one day each week. After 30 days, all forms will be filled out again to examine the sustainability of the training data. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Those who are 18 years of age and over,
- At least 2 months and at most 2 years have passed since the transplant,
- Having a device (phone, tablet, computer, etc.) that can watch the video,
- Patients who are literate will be included in the study.
Key exclusion criteria (2 listed)
- Communication problems occur,
- Patients with distressing medical conditions will be excluded from the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Experimental: 1st Experimental GroupAlso: Video-supported teaching in line with the Health Belief ModelIndividuals will be sent relevant educational videos after liver transplantation and asked to watch them. | Other | 1. Experimental Group |
| Experimental: 2nd Experimental GroupAlso: Video assisted teachingIndividuals will be sent relevant educational videos after liver transplantation and asked to watch them. | Other | 2. Experimental Group |
Primary outcome
Patient Introduction Form
Time frame: 6 months
It is a form prepared by the researcher and examines the sociodemographic and medical characteristics of liver transplant patients. This form includes 11 questions to determine the patients' age, gender, marital status, education level, employment status, income level, how long they have had liver disease, additional diseases, the presence of people assisting in the care, how long ago the transplant was performed, and the donor type.
Chronic Illness Adjustment Scale
Time frame: 6 months
It was developed by Derya Atik and Hilal Karatepe in 2016. The scale consists of 25 items. It consists of three subscales: Physical Adaptation (11 items), Social Adaptation (7 items), and Psychological Adaptation (7 items). Subdimensions of the scale; 1. Physical Harmony; Items 1, 9, 10, 13, 14, 15, 16, 18, 22, 23, 24 (minimum 11, maximum 55 points), 2. Social Cohesion; 2nd, 3rd, 5th, 7th, 17th, 19th, 25th items (minimum 7, maximum 35 points), 3. Psychological Adjustment; Items 4, 6, 8, 11, 12, 20, 21 measure (minimum 7, maximum 35 points). Scoring: 1st, 2nd, 3rd, 4th, 7th, 8th, 9th, 10th, 11th, 13th, 14th, 15th, 16th, 18th, 21st, 22nd, The 23rd items are normal (in the form of 1,2,3,4,5), the 5th, 6th, 12th, 17th, 19th, 20th, 24th, 25th items are reverse (5,4,3,2). It is scored as .1). The total score that can be obtained from the scale is 125. Higher scores from the subscales and/or the entire scale mean that patients' adaptation levels to the disease increase.
Compliance with Immunosuppressive Medication Use Scale
Time frame: 6 months
In the scale developed by Özdemir, the compliance with medication use of patients who have had solid organ transplants and are taking immunosuppressive drugs is evaluated. In order for the scale to be applied, patients must complete at least two months after transplantation. The scale consists of 11 items in total. Scoring is done with a 5-point and 2-point Likert type rating. The scale includes positive and negative expressions. Positive statements are 4 and 6, and negative statements are 1, 2, 3, 5, 7, 8, 9, 10 and 11. Positive statements are scored from 1 to 5, while negative statements are scored from 5 to 1. For positive items, 1 point is given for a 'yes' answer and 5 points are given for a 'no' answer. The lowest score of the scale is 11 and the highest score is 55. As the score from the scale increases, compliance with medication use increases, and as the score decreases, compliance with medication use decreases. Cronbach's alpha value was calculated as 0.611 by Özdemir.
Rational Drug Use Scale
Time frame: 6 months
It consists of 21 items and a single dimension. Items are scored on a 5-point Likert-type scale according to the situations in which they realize the statements (1-Never, 2-Rarely, 3-Occasionally, 4-Often and 5-Always). Only the 17th item in the scale is reverse scored. After the reverse-scored item is translated, the sum of all scale items gives the "total scale score". The total score of AİKÖ varies between 21 and 105. As the total score obtained from ADAS increases, rational drug use increases. When evaluating the total score received from AİKÖ; If the total score is between 21 and 52, it is scored as low, between 53 and 67, as medium, and between 68 and 105, it is scored as high.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Feb 2026.
- Individual participant dataSharing planned: No. It can be used as a source for other research.
Related trials for Education
Not yet recruitingObservational study
Validation of the Healthcare Relationship Assessment Scale (ERA) in Health Sciences Students.
Health Adult Subjects, Communication
RecruitingEarly Phase 1
Developing Transcranial Neuromodulation Protocols for Learning and Decision-Making
Normal Physiology
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Recruiting
Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Not yet recruiting
Mobile Game-Based Versus Classic First Aid Education in Adolescents: Randomized Controlled Trial
First Aid, Health Education in Schoolchildren
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sezai Yılmaz, Prof Dr study director
Turgut Ozal Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Experimental: 1st Experimental Group and Experimental: 2nd Experimental Group in people with Education, run by Inonu University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient Introduction Form (time frame: 6 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2026.